



Scientific Program

March 29th : HCV and Transplant Day

Women in Hepatology

March 29th 7:30-9:00 Room C-2

Moderators: L Li (China), M Omata (Japan)

- 7:30-7:45 Anna S Lok, USA
 7:45-8:00 Nancy Leung, Hong Kong
 8:00-8:15 Karen Lindsay, USA
 8:15-8:30 Marion Peters, USA

Drug Related Mutation

March 29th 7:30-9:00 Room C-1

Moderators: H Zhuang (China), O Yokosuka (Japan)

- 7:30-7:45 Potency and High Resistance Barrier-A Successful Approach to Avoiding Resistance
Richard J Colonno, USA
 7:45-8:00 Antiviral Drug Resistance and HBV: A Virologist Perspective
Stephen Locarnini, Australia
 8:00-8:15 Mutation of HCV Genome and Peginterferon / Ribavirin Combination Therapy
Nobuyuki Enomoto, Japan
 8:15-8:30 Discussion

Recent Advance in Transplantation

March 29th 9:00-10:30 Room C-2

Moderators: G McCaughan (Australia), T Ichida (Japan)

- 9:00-9:15 Liver Transplantation in China 2006
Shu-Sen Zheng, China
 9:15-9:30 Live Donor Liver Transplant for HCC in Asia
Sheung-Tat Fan, Hong Kong
 9:30-9:45 Living Donor Liver Transplantation; Kaohsiung Experience
Chao-Long Chen, Taiwan
 9:45-10:00 Live Donor Liver Transplant for HCV in Japan
Seiji Kawasaki, Japan
 10:00-10:15 Recent Advance of Transplantation in Oceania
Edward Gane, New Zealand
 10:15-10:30 Discussion

HCV "Hot & New"

March 29th 9:00-11:00 Annex

Moderators: ER Schiff (USA), M Omata (Japan)

- 9:00-9:20 Future of HCV Geno 2 and 3 Treatment - A Global View
Michael Manns, Germany
 9:20-9:40 Re-treatment of Non-responders to Interferon Therapy
Karen Lindsay, USA
 9:40-10:00 Insights into Failure of HCV Therapy
Michael Fried, USA
 10:00-10:20 HCV Protease Inhibitors: Antiviral Efficacy and Resistance Profile
Stefan Zeuzem, Germany

Presidential Plenary 2

Hepatitis C

March 29th 11:00-12:00 Annex

Moderators: J Cheng (China), N Enomoto (Japan)

- 11:00-11:10 **O-159**
HCV Modulates RIG-I Signaling Pathway Differently Dependent on HCV Isolates
Shinya Maekawa, Japan
 11:10-11:20 **O-168**
Overweight is an Independent Risk Factor of Hepatocarcinogenesis in Chronic Hepatitis C Patients
Takamasa Ohki, Japan
 11:20-11:30 **O-145**
The E6AP Ubiquitin Ligase Mediates Ubiquitylation and Degradation of Hepatitis C Virus Core Protein
Ikko Shoji, Japan
 11:30-11:40 **O-191**
Telaprevir & Peg-IFN Suppresses Wild-type and Resistant Variants in HCV Genotype-1 Infected Patients
Tara Kieffer, USA
 11:40-11:50 **O-188**
R1626, A Novel Nucleoside Analogue Targeting HCV Polymerase in Chronic HCV Genotype 1 Patients
Graham Cooksley, Australia
 11:50-12:00 **O-196**
Which HCV Genotype 1 Patients may Benefit from Extended Treatment with Peginterferon -2a (40KD)+RBV?
Jose M Sanchez-Tapias, Spain

APASL Consensus Statement: HCV

March 29th 14:00-15:00 Annex

Moderators: G McCaughan (Australia), M Omata (Japan)

Panelist: R Guan (Singapore)
 Panelist: D Amarapurkar (India)
 Panelist: R Tateishi (Japan)
 Panelist: A Chutaputti (Thailand)

APASL Consensus Statement: Portal Hypertension

March 29th 15:00-16:00 Annex

Moderators: SK Sarin (India), Y Chawla (India)

Panelist: BC Sharma (India)
 Panelist: W Jafri (Pakistan)
 Panelist: J Sollano (Philippines)

Scientific Program

March 30th : HCC and NASH Day

Presidential Plenary 3

Hepatocellular Carcinoma

March 30th 7:30-9:00 Annex

Moderators: W Reed (Australia), PJ Chen (Taiwan)

- 7:30-7:40 **O-108**
Effect of Retinoic Acid on Iron Metabolism in Liver
Hiroyuki Tsuchiya, Japan
 7:40-7:50 **O-124**
Genome-wide Screen for Autoimmune Hepatitis Susceptibility and Resistance Genes in Japanese
Kaname Yoshizawa, Japan
 7:50-8:00 **O-265**
Recurrence of PBC and PSC after Living Donor Liver Transplantation in Japan
Satoshi Yamagiwa, Japan
 8:00-8:10 **O-295**
Essential Roles of IKKbeta / NF- B Activation for Development of Liver Metastasis in Mice
Shin Maeda, Japan
 8:10-8:20 **O-377**
A Randomized Trial to Evaluate UFT Adjuvant Therapy to Prevent Postoperative Recurrence of HCC
Kiyoshi Hasegawa, Japan
 8:20-8:30 **O-428**
Endothelial Progenitor Cell Transplantation Reduces Fibrogenesis and Contributes Regeneration in Rat
Toru Nakamura, Japan
 8:30-8:40 **O-429**
Identification of Biomarkers for the Prediction of HBV Related HCC by Integrated Proteomics
George KK Lau, Hong Kong

Meet the Japanese Experts

March 30th 7:30-9:00 Room B-1

Moderators: M Onji (Japan), Y Yamaoka (Japan)

- 7:30-7:45 Environmental Carcinogenesis Revisited
Okio Hino, Japan
 7:45-8:00 Clinical Application of HGF to Fulminant Hepatitis
Hirohito Tsubouchi, Japan
 8:00-8:15 Influence on Viral Factors and Host Genetic Background in Prognosis of Hepatitis C Virus Infection
Sumio Kawata, Japan
 8:15-8:30 Living Donor Liver Transplantation for Hepatocellular Carcinoma in Japan
Satoru Todo, Japan

HCC Pathogenesis / Diagnosis

March 30th 9:00-10:00 Annex

Moderators: H Thomas (UK), K Okita (Japan)

- 9:00-9:15 The Biological Significance of DCP (PIVKA-2)
Brian I Carr, USA
 9:15-9:30 Transcriptional Signature of Hepatocellular Carcinoma
Shuichi Kaneko, Japan
 9:30-9:45 Imaging Diagnosis of Early-stage HCC
Masatoshi Kudo, Japan
 9:45-10:00 Discussion

HCC Natural Course and Treatment

March 30th 10:00-11:00 Annex

Moderators: M Monden (Japan), M Miyazaki (Japan)

- 10:00-10:20 Radiofrequency Ablation for HCC
Shuichiro Shiina, Japan
 10:20-10:40 Hepatic Resection for HCC
Tadatoshi Takayama, Japan
 10:40-11:00 Discussion

Okuda Memorial

March 30th 11:00-12:00 Annex

Moderators: G Farrell (Australia), M Omata (Japan)

Hepatology Training in Asia
 A Kadir Dokmeci, Turkey
 Shiv K Sarin, India
 Jose Sollano, Philippines
 Laurentius A Lesmana, Indonesia
 Wan-Long Chuang, Taiwan

APASL-KASL

March 30th 9:00-11:30 Room B-1

Session 1: Acute Hepatitis

Moderators: KS Rim (Korea), SR Kim (Japan)

- 9:00-9:15 Hepatitis E in Japan
Jong-Hon Kang, Japan
 9:15-9:30 Hepatitis A in Korea
So Young Kwon, Korea

Session 2: Chronic Hepatitis B

Moderators: YS Lee (Korea), SJ Byun (Japan)

- 9:30-9:50 Epidemiologic and Genotypic Characteristics of HBV in Korea
Si Hyun Bae, Korea
 9:50-10:10 Antiviral Resistance in Korea
Young-Suk Lim, Korea

Session 3: Liver Cirrhosis and HCC

Moderators: HS Lee (Korea), YS Ku (Japan)

- 10:10-10:30 Hepatic Fibrogenesis
Norifumi Kawada, Japan